Minnow Street Minnow Street
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Monte Rosa Therapeutics Inc (GLUE)

Healthcare Biotechnology
16.50 $
-27.2% vs. previous close
Closing price · As of: 31. Jul 2026

Who owns Monte Rosa Therapeutics Inc (GLUE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 62.7% of the shares are freely tradable; institutional investors hold 113.2%.

Ownership Structure

Institutional ownership
113.2%
Insiders
0.6%
Float
62.7%
Short % of float
20.7%
Shares Outstanding
85Mio.

Largest Shareholders

Institutions

Institutions GLUE
Name Stake (%) Shares Change (%) Date
NEA Management Company, LLC 9.11 7,692,298 +0.0 03/31/2026
T. Rowe Price Associates, Inc. 7.95 6,720,188 +31.3 03/31/2026
BlackRock Inc 6.67 5,637,684 +34.8 03/31/2026
TCG Crossover Management, LLC 5.47 4,622,151 +0.0 03/31/2026
Bvf Inc 5.28 4,460,886 +16.3 03/31/2026
Baker Bros Advisors LP 5.14 4,345,736 +0.0 03/31/2026
Suvretta Capital Management, LLC 5.00 4,226,809 +25.8 03/31/2026
Vestal Point Capital LP 4.27 3,603,465 +365.0 03/31/2026
State Street Corp 3.97 3,353,980 +59.1 03/31/2026
Vanguard Group Inc 3.84 3,246,500 +8.6 12/31/2025

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
16. Jul 2026 Warmuth Markus President & CEO Sell 9,500 23.18 220,219
15. Jul 2026 Champoux Jennifer Chief Operating Officer Sell 4,351 23.38 101,730
15. Jul 2026 Champoux Jennifer Chief Operating Officer Other 4,351 3.98 17,317

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?